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Abstract
Background
Assays have been developed for cross-sectional HIV incidence estimation using plasma
samples. Large scale surveillance programs are planned using dried blood spot (DBS)
specimens for incidence assessment. However, limited information exists on the perfor-
mance of HIV cross-sectional incidence assays using DBS.
Methods
The assays evaluated were: Maxim HIV-1 Limiting Antigen Avidity EIA (LAg-Avidity), Sedia
HIV-1 BED-Capture EIA (BED-CEIA), and CDC modified BioRad HIV-1/2 Plus O Avidity-
based Assay (CDC-BioRad Avidity) using pre-determined cutoff values. 100 matched HIV-1
positive plasma and DBS samples, with known duration of infection, from the Consortium
for the Evaluation and Performance of HIV Incidence Assays repository were tested. All
assays were run in duplicate. To examine the degree of variability within and between
results for each sample type, both categorical and continuous results were analyzed. Asso-
ciations were assessed with Bland Altman, R2 values and Cohen’s kappa coefficient (ĸ).
Results
Intra-assay variability using the same sample type was similar for all assays (R2 0.96 to
1.00). The R2 values comparing DBS and plasma results for LAg-Avidity, BED-CEIA, and
CDC-BioRad Avidity were 0.96, 0.94, and 0.84, respectively. The concordance and ĸ values
between DBS and plasma for all three assays were >87% and >0.64, respectively. The
Bland-Altman analysis showed significant differences between plasma and DBS samples.
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For all three assays, a higher number of samples were classified as recent infections using
DBS samples.
Conclusions
DBS and plasma sample results were highly correlated. However, when compared to
plasma, each assay performed somewhat differently in DBS at the lower and higher ends
of the dynamic range. DBS samples were more likely to be classified as recently infected
by all three assays, which may lead to overestimation of incidence in surveys using per-
formance criteria derived for plasma samples.
Background
HIV incidence is the number of new infections that occur over a period of time in a particular
population [1]. Measurements of HIV incidence are used to study the HIV/AIDS epidemic,
determine populations and geographic areas at higher risk for infection, and evaluate the effi-
cacy of interventions targeted towards these higher risk groups [2, 3]. Serological assays are
one of the methods utilized to screen populations for HIV incidence. Almost all data currently
available on the performance of incidence has been generated on stored serum or plasma sam-
ples [4–7]. Very little information is currently available on the use of dried blood spots (DBS)
for cross sectional incidence testing. However, it would be beneficial if DBS samples could be
used with these assays, particularly when large studies are conducted in resource-poor settings.
The drawbacks to using plasma and serum include the invasive nature of drawing blood, the
processing required to separate plasma and serum from whole blood, and the need for cold
transport and storage. In contrast, dried blood spots are collected through a minimally invasive
procedure and can be stored and transported at ambient temperature up to 14 days after col-
lection [8].
Very little data on the performance of HIV incidence assays on DBS samples has been pub-
lished in peer reviewed publications, independent of developers of these incidence assays. One
previous study, presented at a scientific conference [9], directly examined the results of Maxim
HIV-1 Limiting Antigen Avidity EIA (LAg-Avidity) from matched DBS and plasma. They
determined that there was a high correlation between sample type for both continuous and
categorical results. One other published study explored the use of DBS on an HIV incidence
assay using the Calypte HIV-1 BED Incidence EIA. However, the DBS results were not com-
pared to matched plasma results so it is unclear if the DBS results obtained are comparable to
the results that would have been generated using plasma [10]. To further investigate the use of
DBS samples to screen populations for HIV incidence, we tested matched plasma and DBS
samples on LAg-Avidity, Sedia BED HIV-1 Incidence EIA (BED-CEIA), and CDC-BioRad
Avidity [4, 11, 12].
Methods
Ethics statement
This study was approved by the Institutional Review Board of the University of California at
San Francisco School of Medicine (IRB# 10–02365, Title: The HIV Panels Project and develop-
ment and evaluation of assays to detect recent HIV infection and estimate HIV incidence) and
the Johns Hopkins School of Medicine eIRB2 (IRB# NA00004380, Title: HIV Prevention Trials
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Network: Laboratory Center). All trial and cohort studies were conducted according to the
ethical standards set forth by the institutional review boards of the participating institutions
and the Helsinki Declaration of the World Medical Association. All participants provided writ-
ten informed consent. This report includes analysis of stored samples and data from those
studies.
Sample characteristics and storage
100 matched plasma and DBS samples were obtained from the Consortium for the Evaluation
and Performance of HIV Incidence Assays (CEPHIA). DBS samples were prepared at three
different testing sites, one in the United States, and two in Brazil. The site in the United States
contributed 75 samples while the sites in Brazil contributed 25 samples total. DBS samples
were prepared by pipetting 50 μl of whole blood per spot from a fresh tube of venous whole
blood in EDTA onto Whatman1 903 Protein Saver Cards. The volume of whole blood used
to make blood spots is important, since it has been shown that the volume of serum obtained
from a 6 mm punch increases with increasing spot volume if the hematocrit is kept constant
[13].
All samples were positive for HIV and had a known duration of infection. For the purposes
of this study, those samples from individuals known to be infected < 1 year were classified as
‘recent’ while those samples from individuals known to be infected >1 were classified as ‘long
term’. Other sample characteristics are shown in Table 1. The plasma samples were stored at
−80˚C and the DBS samples were stored at −20˚C.
Sample preparation
When preparing the DBS for elution, 6 mm punches were taken from each sample, which con-
tained approximately 13 μl of whole blood. Forceps were used to transfer the sample punches
Table 1. Characteristics of matched plasma and DBS samples.
Characteristic N
Duration of Infection
>1 year 75
<1 year 25
Viral Load
>10,000 31
400–10,000 21
<400 40
Unknown 8
CD4 Cell Count
>500 58
200–500 33
50–199 2
<50 0
Unknown 7
On ART
No 76
Yes 24
Country
Brazil 25
United States 75
doi:10.1371/journal.pone.0172283.t001
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into the appropriate titer tubes. Titer tubes are 1.2 mL polypropylene tubes that do not have
caps and are disposable. They come in a rack of 96 tubes. After each transfer, the forceps were
wiped with a 70% ethanol solution and allowed to dry before being used again. Furthermore,
six blank punches were made between each DBS sample punch (6 mm diameter) in order to
reduce the possibility of contamination. These blank punches were not eluted.
DBS samples were eluted overnight at 4˚C without agitation for all three assays. The fol-
lowing elution volumes were used: LAg-avidity: 500 μl; BED-CEIA: 400 μl; CDC-BioRad
Avidity: 300 μl. The sample diluent used for each assay was provided by the respective man-
ufacturer. A previous study found that at a 55% hematocrit, a 6 mm punch from a 50 μl
spot contains approximately 5.5 μl of serum[13]. Using this estimation of the volume of
serum in a 6 mm punch from a 50 μl spot at a 55% hematocrit, it can be determined that
less than 2 μl of sample is entered into each test. This volume is calculated by taking into
account the volume of sample diluent used for elution and the amount of eluate required
for each assay. The required eluate volume for LAg-Avidity, BED-CEIA, and CDC-BioRad
Avidity is 100 μl. Thus, the estimated volume of serum added per well to each assay is as fol-
lows: LAg-Avidity: 1.10 μl; BED-CEIA: 1.38 μl; and CDC-BioRad Avidity: 1.83 μl. These
estimated values demonstrate that less serum is added to the above assays when using DBS
samples compared to traditional serum samples.
For CDC-BioRad Avidity, the incident DBS controls were made from an HIV seroconver-
sion panel purchased from Zeptometrix Corporation (Catalog No. HIV 9081, panel members
9081–03 and 9081–04) and the prevalent controls were made from a plasma sample collected
from an individual known to have a long-term HIV infection. To prepare the DBS controls for
CDC-BioRad Avidity, control plasma samples were mixed with red blood cells at a 40% hemat-
ocrit; 50 μl of this mixture was then spotted onto Whatman1 903 Protein Saver Cards. The
cards were dried overnight and then placed in sealed bags with desiccant packs and humidity
indicators and stored at -20˚C prior to use. The DBS controls used with LAg-Avidity and
BED-CEIA were provided in their respective kits[14].
Sample testing
All sample testing was performed in a single, centralized laboratory by one technician. Samples
were tested in duplicate on LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity. The manufac-
turer’s protocol was followed for both the plasma and the DBS testing done using LAg-Avidity
and BED-CEIA. The CDC-BioRad Avidity testing was completed using the protocol optimized
by the CDC for both sample types. The BioRad Avidity protocol optimized by the CDC pro-
vides a result known as an avidity index (AI). Avidity index values are ratios of the optical den-
sity (OD) values obtained from two different test wells for each sample. During the antibody
dissociation step of the assay, one well is treated with BioRad wash buffer and one well is
treated with 0.1 M diethylamine (DEA). The DEA reagent dissociates antibodies that are
weakly bound to the target antigens. The OD value from the DEA-treated well is divided by
the OD value from the wash buffer-treated well and multiplied by 100 to obtain the AI, which
is expressed as a percentage[4]. Further description of this assay modified for use in DBS can
be found in the recently published manuscript by Wei and colleagues[15]. Duplicate samples
were run on the same plate for BED-CEIA and LAg-Avidity and on different plates for
CDC-BioRad Avidity. Matched plasma and DBS samples were run on the same plate for Sedia
BED and CDC-BioRad Avidity. Conversely, the matched plasma and DBS samples were run
on different plates for Maxim LAg-Avidity because Maxim manufactures separate kits for
plasma and DBS testing that have different lot numbers. Each time a DBS sample was run on
an assay a single 6 mm punch was used.
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Statistical methods
Both continuous and categorical results were analyzed to determine the degree of variability
within and between sample type results. Correlation between continuous results was evaluated
using Pearson’s correlation coefficient (r), R2, and Bland-Altman plots, while correlation
between categorical results was assessed using Cohen’s kappa coefficient (ĸ). The cutoff for
determining recent and long-term infection was 1.5 OD-n for LAg-Avidity, 0.8 OD-n for
BED-CEIA, and 30% AI for CDC-BioRad Avidity. These cutoffs were established using serum
or plasma samples. Statistical analyses were performed in STATA version 11 (StataCorp, Col-
lege Station, TX).
Results
Correlation between continuous results
Variability within sample type was low for both plasma and DBS. The R2 value was 0.99 for
plasma samples run on LAg-Avidity and BED-CEIA and 0.96 for plasma samples run on
CDC-BioRad Avidity. Similarly, R2 was 1.00, 0.99, and 0.97 for DBS samples run on LAg-Avid-
ity, BED-CEIA, and CDC-BioRad Avidity, respectively (Table 2). These R2 values are based on
the replicates of each sample. For variability between plasma and DBS results the R2 values were
0.96, 0.93, and 0.84, for LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity, respectively (Fig 1).
When using a cutoffs of 1.5 or 3.0 OD-n with the LAg-Avidity assay, the average difference
of OD-n values indicates that both plasma and DBS samples had greater variability above the
assay cutoffs than below the assay cutoffs. For plasma samples, using a cutoff of 1.5 OD-n, repli-
cates had an average difference of 0.18 (SD: 0.17) for values above the cutoff and an average
difference of 0.03 (SD: 0.04) for values below the cutoff. Using a cutoff of 3.0 OD-n, plasma rep-
licates had an average difference of 0.19 (SD: 0.18) above the cutoff and 0.08 (SD: 0.10) below
the cutoff. For DBS samples, using a cutoff of 1.5 OD-n, replicates had an average difference of
0.11 (SD: 0.09) for values above the cutoff and an average difference of 0.06 (SD: 0.05) for values
below the cutoff. Using a cutoff of 3.0 OD-n, DBS replicates had an average difference of 0.11
(SD: 0.09) for values above the cutoff and 0.07 (SD: 0.05) for values below the cutoff.
Table 2. R2 values for replicate plasma and DBS samples tested with LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity.
LAg-Avidity BED-CEIA CDC-BioRad Avidity
Plasma 0.99 0.99 0.96
DBS 1.00 0.99 0.97
doi:10.1371/journal.pone.0172283.t002
Fig 1. Correlation of results from matched plasma and DBS samples tested with LAg-Avidity, BED-CEIA, and CDC-BioRad
Avidity.
doi:10.1371/journal.pone.0172283.g001
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Comparing the three assays, the average differences of the OD-n values of plasma replicates
run on LAg-Avidity and BED-CEIA were 0.14 (SD: 0.16) and 0.08 (SD: 0.07), respectively. In
contrast, the average difference of the OD-n values of matched plasma and DBS samples was
0.74 (SD: 0.55) for LAg-Avidity and 0.26 (SD: 0.33) for BED-CEIA. The average difference of
the AI values of plasma replicates run on CDC-BioRad Avidity was 0.05 (SD: 0.07) while the
average difference of the AI values of matched plasma and DBS samples was 0.09 (SD: 0.12)
(Table 3).
The Bland-Altman plots showed significant differences between plasma and DBS results
(Fig 2). For the LAg-Avidity assay there was an increase in the plasma values relative to the
DBS values as the average OD-n increased. When the OD-n was 2 the DBS value was 0.5 OD-
n less than the plasma value. At the high OD-n values there was a full unit difference between
DBS and plasma. For the BED-CEIA, DBS-plasma differences were minimal at the low OD-n
(values < 1.0) and greater at the high values, but differences occurred in both directions. For
the CDC-BioRad Avidity assay the variation between DBS and plasma was greatest at the
lower values: among values with an AI of 40% or less, DBS and plasma measurements differed
by up to 20% of the AI value.
Correlation between categorical results
Compared to plasma, a higher proportion of DBS samples were classified as recent for all three
assays (Fig 3). The concordance values between DBS and plasma for LAg-Avidity, BED-CEIA,
and CDC-BioRad Avidity were 95%, 93%, and 87%, respectively. The ĸ values between DBS
and plasma for LAg-Avidity, BED-CEIA, and CDC-BioRad Avidity were 0.88, 0.85, and 0.64,
respectively. When comparing categorical assay results to clinically determined categories,
plasma samples had higher concordance and ĸ values than DBS for all assays, and the ordinal
Table 3. Average differences (standard deviations) of replicate plasma samples and matched plasma and DBS samples tested with LAg-Avidity,
BED-CEIA, and CDC-BioRad Avidity.
LAg-Avidity BED-CEIA CDC-BioRad Avidity
Plasma (replicates on same plate) 0.14 (0.16) 0.08 (0.11) n/a
Plasma (replicates run on different plates) n/a n/a 0.05 (0.07)
DBS versus plasma 0.74 (0.55) 0.26 (0.33) 0.09 (0.12)
doi:10.1371/journal.pone.0172283.t003
Fig 2. Bland-Altman plots of results obtained from testing matched plasma and DBS samples with LAg-Avidity, BED-CEIA, and CDC-BioRad
Avidity.
doi:10.1371/journal.pone.0172283.g002
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rank of assays for concordance with plasma was the same for plasma and for DBS. The
CDC-BioRad Avidity had the fewest misclassified samples for both plasma (concordance:
90%; ĸ: 0.3) and DBS (concordance: 81%; ĸ: 0.48). Seven DBS samples were excluded from the
CDC-BioRad Avidity analysis due to protocol guidelines, which state that any sample that has
a wash well OD value below the assay cutoff should not have an AI calculated.
Discussion
DBS and plasma results were highly correlated for the assays that were examined. However,
DBS samples were more likely than plasma to be classified as recent for all three assays, suggest-
ing that using DBS may result in an over-estimation of incidence in surveys using performance
criteria derived for plasma samples. Thus, it may be necessary to adjust the DBS protocols for
these assays or make appropriate changes to the cutoffs when DBS samples are used. Moreover,
the Bland-Altman analysis demonstrates that the variation between the continuous results
obtained from plasma and DBS differs by assay. This analysis also demonstrates that matched
plasma and DBS samples have more variability at the higher end of the range of OD-n values
for LAg-Avidity, which reflects the trend among both plasma and DBS replicate average differ-
ences. For both sample types, the average difference in LAg-Avidity OD-n values is greater
above 1.5 OD-n compared to below 1.5 OD-n.
There were several limitations to this study. Firstly, the sample size was relatively small.
Also, due to the finite sample amount it was not possible to compare inter-technician or inter-
laboratory variability between the plasma and DBS results. Also, it was unfeasible to examine
the reproducibility between lot numbers of a particular kit. In the future, it would be beneficial
Fig 3. Comparison of categorical results obtained from epidemiologic data and results obtained by testing plasma
and DBS samples. Results from LAg-Avidity (highlighted in blue), BED-CEIA (highlighted in green), and CDC-BioRad Avidity
(highlighted in pink).
doi:10.1371/journal.pone.0172283.g003
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to screen larger numbers of matched plasma and DBS samples for HIV incidence using the
same assays to confirm the results that are presented above. A possible reason for the variation
in performance is that we did not control for hematocrit and punch location bias [16]. Punch
location can be easily controlled given sufficient sample size available on the DBS card so that
partial-spot punches can be avoided. The additional testing needed to control hematocrit con-
centrations would greatly increase the cost and complexity of performing DBS based incidence
assays. However, previous research demonstrated that when blood spot volume remains con-
stant, the volume of serum obtained from a 6 mm punch varies with the hematocrit of the orig-
inal blood sample [13]. Moreover, antiretroviral treatment and viral suppression are associated
with false-recent incidence assay test results. This reflects down-regulation of anti-HIV anti-
bodies when the level of circulating antigen is reduced [17, 18].
In our study we used a simple classification based on one year infection as the definition of
recent infection. Further investigation is warranted to determine if the mean duration of
recent infection (MDRI) and the false recent rate (FRR) are influenced by the source (plasma
vs. DBS) of the sample, as these are the true performance metrics of a cross-sectional incidence
assay or algorithm[19]. These studies require larger sample sizes to accurately determine if
there are significant differences in MDRI and FRR.
Supporting information
S1 Data. All data used in analyses. OD is optical density, OD-n is normalized optical density,
and AI is the avidity index. “Wash” refers to the sample well that had wash buffer added to it
during the dissociation step of CDC-BioRad Avidity and “DEA” refers to the sample well that
had DEA added to it during this assay step. The country abbreviations are as follows: United
States (US) and Brazil (BR). For the column titled “ARV Treated at Draw,” FALSE means that
the individual was not on ARV treatment when the sample was drawn and TRUE means that
the individual was on ARV treatment. For the column titled “Duration of Infection,” 0 means
that the individual was infected for less than 1 year and 1 means that the individual was infected
for more than 1 year.
(XLSX)
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